Vaxxas Initiates Program With Merck to Optimize Delivery of Next Generation Vaccines Utilizing Novel Mechanism for Immune System Activation

You may also like

28 May 2020

Harro Höfliger and Vaxxas announce alliance to develop industrial‐scale aseptic processing line for vaccine products based on Vaxxas’ High Density Microarray Patch (HD‐MAP)

30 April 2020

Clinical Genomics expands strategic relationship with Quest Diagnostics and further increases momentum for innovative first-line colorectal cancer screening blood test

08 October 2012

Vaxxas Initiates Program With Merck to Optimize Delivery of Next Generation Vaccines Utilizing Novel Mechanism for Immune System Activation

31 October 2013

Hatchtech completes $12.5M capital raise, secures funds for phase III trial and NDA submissions, and announces board changes

18 October 2016

Data published in Cancer Medicine Demostrate Clinical Genomics’ Blood Test for Colorectal Cancer Recurrence is Two-Fold More Sensitive than CEA Test

26 October 2010

Hatchtech raises $6.3m for DeOvo™ Head Lice Phase 2b Clinical Trial

View All

Ventured. Gained.

Subscribe to our Newsletter for the latest updates from 1V.

decor decor decor
decor decor decor decor decor